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We recently reported that 95% of chondroblastomas harbours a p.Lys36Met 
(p.K36M) mutation in either the H3F3A (choromosome 1) or H3F3B genes 
(chromosome 17), with the majority involving H3F3B.  In this study we sought to 
assess the expression of the K36M-mutated protein by immunohistochemistry in 
a large group of tumours. 
Methods and Results 
1894 tumours, including 85 chondroblastomas and 10 clear cell chondrosarcomas 
were studied, of these 82 chondroblastomas and 1 clear cell chondrosarcoma, 
known to harbour the H3F3 K36M mutation, expressed the mutated protein. 3 
chondroblastomas and 9 clear cell chondrosarcomas wild-type for H3F3A/B were 
negative for K36M immuno-expression. The remaining 1799 cases tested, 545 of 
which were known to be wild-type for the H3F3A and H3F3B K36M substitutions, 
included 1047 primary bone tumours, 507 soft tissue and joint tumours. 245 other 
tumour types not expected to harbour the mutation were negative for K36M 
immunohistochemistry.  
Conclusions 
Our data demonstrate the specificity and sensitivity of this immunomarker and 






Chondroblastoma is a rare benign central cartilaginous bone tumour1 
representing less that 1% of all primary bone tumours. Histologically, 
chondroblastoma has a characteristic heterogeneous appearance comprising 
sheets of discohesive neoplastic mononuclear cells with small grooved nuclei2, 3 
mixed and variable numbers of osteoclast-like giant cells: the latter can dominate 
or can be scant. Islands of eosinophilic chondroid (chondroid-osseous) matrix are 
also present whereas hyaline cartilage is uncommon. Pericellular ‘chicken wire’ 
calcification, when present, is a useful diagnostic feature. Mitoses can be frequent 
but atypical forms are not seen. Secondary aneurysmal cyst formation occurs 
commonly. Although the tumour is usually recognised to the ‘trained eye’, the 
heterogeneous composition of the tumour can be challenging particularly on 
biopsy material when the tumour occurs at unusual sites and outside the classic 
subarticular location3. 
 
The differential diagnosis of a chondroblastoma is extensive, including benign and 
malignant neoplasms. These comprise primary bone tumours including 
conventional cartilaginous tumours, and others such as clear cell chondrosarcoma 
which like chondroblastoma occurs in a subarticular site, and chordoma, in 
addition to osteoclast-rich tumours, bone-forming tumours, and fibrous dysplasia 
with areas of cartilage3, 4. A second group includes metastatic neoplasms to bone, 
although this is rarely a diagnostic challenge. 
 
By combining our recent 2 studies we have found that 95% of chondroblastomas 
harbours a p.Lys36Met (p.K36M) mutation in either the H3F3A (choromosome 1) 
or H3F3B genes (chromosome 17), with the majority involving the latter2, 3. We 
also reported that H3F3A alterations were found in 96% (132/139) of giant cell 
tumours of bone3, the majority of which harboured a p.Gly34Trp (p.G34W) 
mutation. In addition, 3 cases revealed a p.Gly34Leucine (p.G34L) alteration, and 
2 tumours revealed a  p.G34R  mutation, one in H3F3A, one in H3F3B:  a G34M 
mutation in H3F3A was detected in a single tumour. The H3F3 G34W and the 
K36M substitutions were mutually exclusive2, 3.  These H3F3 mutations were 
highly specific for chondroblastoma and giant cell tumour of bone and the same 
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alterations were detected in only 2/103 osteosarcomas (one p.G34R in H3F3A, 
one p.G34R mutation in H3F3B), 1/15 clear cell chondrosarcoma and 1/75 central 
chondrosarcomas with a H3F3B p.K36M alteration1, 4. Since then, others have 
reported another H3F3A mutation in one other osteosarcoma (1/10, p.G34W)5.  
 
Detecting a tumour type-specific nucleic acid substitution for diagnostic purposes 
is generally achieved by analysis of a variety of sequencing or PCR-based 
methodologies such as targeted DNA sequencing, exome and whole genome, 
droplet digital PCR and pyrosequencing amongst others. Each of these methods 
has benefits but they are not always available to diagnostic laboratories. Many of 
these approaches involve extensive analyses of panels of 10s to 1000s of genes, 
which is excessive when the aim is to confirm a suspected diagnosis made on a 
haematoxylin and eosin-stained tissue section. Furthermore, molecular genetic 
testing on extracted DNA remains expensive (from hundreds to thousands of 
dollars/pounds) and generally takes a minimum of a week with more extensive 
panels taking longer (http://www.foundationmedicine.com). In contrast 
immunohistochemistry is delivered at a significantly lower cost and within 24 
hours. We therefore undertook this study to determine the utility of a K36M 
mutant antibody for helping to reach a diagnosis of chondroblastoma, and exclude 
other neoplasms.  H3F3 alterations have also been reported in paediatric brain 
tumours6-9, specifically in up to 60% of diffuse intrinsic pontine gliomas6, 9. 
However, as these do not enter the differential diagnosis of bone and soft tissue 
tumours, we have excluded them from this study. 
 
Materials and Methods 
An electronic search of the pathology archives at the Royal National Orthopaedic 
Hospital, UK was undertaken to identify the histopathological diagnoses of 
interest. The tumours were classified using the criteria of the most recent WHO 
classification of soft tissue and bone1. Many of the samples selected for the study 
had already been used to construct tissue microarrays and in some cases it was 
known that the tumour harboured a H3F3 mutation as the DNA had been analysed 
for the mutation using a variety of technologies including whole genome 
sequencing, exome sequencing, capillary sequencing, targeted next generation 
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sequencing (Ion Torrent, targeted capture, and sequencing, and droplet digital 
PCR). In the majority of such cases the result of the p.K36M mutation was 
validated using at least 2 of these techniques2, 3.  
 
We performed immunohistochemistry on 2 chondroblastomas which had been 
decalcified in nitric acid: immunoreactivity in these samples was patchy and weak 
(data not shown). Greater numbers were not available as we normally decalcify 
curettage specimens in EDTA. On the basis of this, samples decalcified in nitric 
were excluded from this study.  
 
Either full tissue sections or sections of tissue microarrays were cut for 
immunohistochemistry as previously described10. In brief, tissue microarrays in 
formalin-fixed paraffin-embedded blocks were constructed using a manual 
arrayer (Beecher Instrument, Sun Prairie, WI, USA). Duplicate 1.0 mm diameter 
cores were taken from each case.   
 
The rabbit monoclonal histone H3 K36M mutant antibody (Clone RM193, RevMAb 
Biosciences USA Inc., CA, USA)_ was kindly provided as a gift by RevMAb 
Biosciences USA Inc. Immunohistochemistry was performed using the Leica Bond 
3 fully automated immunohistochemistry stainer (Leica Microsystems Ltd., Milton 
Keynes, UK). Leica epitope retrieval 2 solution was used for 20 minutes. The 
antibody was diluted in 1/400. 
Ethical approval was obtained from the Cambridgeshire 2 Research Ethics Service 
for the UCL biobank for health and disease (reference 09/H0308/165, renewed 
2015, 15/YH/0311) project EC17.1. The biobank is covered by the Human Tissue 
Authority licence 12055. 
 
Results 
Immunohistochemistry undertaken using the rabbit monoclonal H3F3 K36M 
mutant antibody (Clone RM193) revealed that all 82 chondroblastomas 
harbouring the H3F3 p.K36M mutation (7= H3F3A; 75=H3F3B) expressed the 
mutated protein (Figure 1, Table 1). Three cases which failed to reveal 
immunoreactivity for the H3F3 p.K36M substitution were wild-type for the H3F3 
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p.K36 as assessed by genotyping. Immuno-labelling on multiple tissue blocks from 
these cases failed to reveal a positive reaction.  
 
 The 1/10 clear cell chondrosarcomas reported previously to harbour the K36M 
alteration using next generation sequencing2 was found to be immunoreactive 
with the K36M antibody.  
 
The K36M mutant antibody is directed against a nuclear protein and the 
immunoreactivity revealed crisp nuclear expression with virtually no cytoplasmic 
or matrix reactivity. Immunoreactivity was seen throughout the tumour. The 
antibody proved valuable in identifying immunoreactive cells in small clusters of 
cells in biopsy specimens (Figure 1).  
 
Table 1 lists 1047 primary bone tumour cases (excluding chondroblastoma and 
clear cell chondrosarcoma) that are not immunoreactive for the H3F3 p.K36M 
mutation: 545 of these samples are known not to harbour the mutation (see 
references in Table). Notably none of the giant cell tumours of bone with the HF3F 
p.G34 mutation showed immunoreactivity, and the 2 osteosarcomas (one p.G34R 
mutation in H3F3A, one p.G34R mutation in H3F3B), and the single 
chondrosarcoma with the p.G34W alterations revealed no immunoreactivity for 
the mutant protein 2, 3.  
 
Finally, immunohistochemistry was performed on 752 tumours comprising a 
wide variety of types the DNA of which had not been analysed for the presence of 
a H3F3 K36M mutation (except for 42 tenosynovial giant cell tumours which were 
shown previously to be wild-type for the p.K36M alteration) (Table 1). Some of 
these lesions, such as soft tissue chondroma, plasma cell tumours and clear cell 
carcinomas, were chosen specifically as they can mimic chondroblastoma. 
However, to provide additional evidence for the specificity of the antibody we 
extended the immunohistochemistry testing to other varieties of bone and soft 
tissue tumours, carcinomas and other neoplasms, none of which  has ever been 
shown to harbour a H3F3 p.K36M mutation (http://cancer.sanger.ac.uk/cosmic). 




We have demonstrated that the H3F3 K36M mutant monoclonal antibody (Clone 
RM193) used in this study is highly specific for tumours which harbour this 
mutation. To our knowledge this antibody has not been reported in previous 
studies.  82/82 chondroblastomas and 1/1 clear cell chondrosarcoma which were 
shown to possess this precise genetic alteration through analysis of extracted DNA 
revealed unequivocal immunoreactivity with this antibody. Furthermore, the 3 
chondroblastomas and the 10 clear cell chondrosarcomas which did not harbour 
the mutation as assessed by DNA analysis failed to reveal immunoreactivity.  As 
expected, the immunohistochemistry revealed positivity in the tumours with the 
mutation in either H3F3A or H3F3B, as these represent parologous genes, with the 
same amino acid sequence, on different chromosomes.  The specificity of this 
antibody for the mutant protein is further supported by the absence of immuno-
positivity in at least 545 primary bone tumours comprising different types, which 
we have shown not to harbour the H3F3 p.K36M alteration2, 3. 
 
The analysis of another 1254 other tumour types, including a variety of primary 
bone tumours, carcinomas and other neoplasms in which the mutation would not 
be expected to be expressed http://cancer.sanger.ac.uk/cosmic supports the 
findings that this H3F3 K36M antibody is specific for the mutant protein.  
 
The antibody was simple to optimise for use and we observed that it decorates 
crisply the nucleus of the mononuclear neoplastic population, on formalin-fixed 
paraffin-embedded tissue sections. We detected virtually no background 
immunoreactivity in the cytoplasm of the immuno-positive cells. Furthermore, 
neither the osteoclasts, representing a ‘passenger’ population in the tumour2 nor 
the extracellular cartilaginous matrix revealed any immunoreactivity. A number 
of the paraffin tissue blocks were at least 10 years old and where relevant the 
samples were strongly immunoreactive.   
 
Our results demonstrate that this H3F3 K36M antibody is highly sensitive and 
specific for the p.K36M mutation, and as 96% of chondroblastomas harbour a 
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p.K36M mutation this antibody represents a valuable tool that can be used to 
support the histological diagnosis of chondroblastoma1.  The antibody can be 
employed to distinguish chondroblastoma from other primary bone tumours that 
represent histological mimics of which there are several on account of the 
morphological heterogeneity of this neoplasm. Furthermore, as only ~4% of 
chondroblastoma do not harbour a H3F3 K36M mutation, failing to detect it, 
should make the pathologist consider other diagnoses, and chondroblastoma 
should only be diagnosed with caution.   
 
Apart from chondroblastoma, the only other bone or soft tissue tumour in which 
a p.K36M mutation was detected was the clear cell chondrosarcoma, a malignant 
bone tumour only accounting for 2% of all chondrosarcoma1. However, as 
reported previously the mutation was detected in a minority of cases analysed 
(1/15) (with only 10 cases being available for immunohistochemistry)2. Clear cell 
chondrosarcoma has many overlapping clinical and radiological features with 
chondroblastoma including the anatomical site (subarticular and apophyseal) but 
clear cell chondrosarcoma requires an en bloc wide excision whereas 
chondroblastoma is generally curetted. Clear cell chondrosarcoma presents most 
commonly in the proximal femur and humerus in the 3rd - 4th decades, whereas 
chondroblastoma presents most commonly in the distal femur and proximal tibia 
in the 2nd and 3rd decades. However, both can present over the age of 40, and in 
any bone in the body.  On imaging, clear cell chondrosarcoma can be challenging 
to distinguish from chondroblastoma as signal intensity of both tumour types on 
magnetic resonance imaging is very heterogeneous. Although clear cell 
chondrosarcoma is generally larger, and has less pronounced peritumoural 
oedema and joint synovitis than chondroblastoma these criteria are not 
sufficiently reliable to distinguish the 2 entities11. Histologically, clear cell 
chondrosarcoma is characterised by sheets of well-defined cells with clear – 
slightly eosinophilic cytoplasm: mitotic figures are rare and osteoclast-like cells 
can be present in large numbers.  Zones of conventional chondrosarcoma with 
hyaline cartilage can be present, and there are foci of woven bone and ossification. 
A greater degree of cellular atypia, the presence of hyaline cartilage and 
entrapment of host bone are helpful in reaching the diagnosis. Nevertheless, this 
 9 
is can be challenging on a needle core biopsy.  
 
There are reports that TP53 mutations occur in 95% of clear cell 
chondrosarcoma12 whereas they have not been detected in 25 chondroblastoma2, 
3. Therefore, testing for the presence of such pathogenic variants would be 
valuable for distinguishing these 2 neoplasms, although analysis of greater 
numbers would be necessary to establish this firmly.  
 
Chondroblastoma can share occasionally morphological appearances with 
conventional central/ surface cartilaginous tumours, mesenchymal 
chondrosarcoma  which are characterised by HEY1-NCOA2 fusion genes13, and 
chondromyxoid fibroma. The failure to show immunoreactivity for the K36M 
antibody in these tumours demonstrates the value of this marker.    
 
Distinguishing chondroblastoma from a chondroblastic osteosarcoma can be 
challenging, not only because of the morphological overlap but also because on 
rare occasions chondroblastomas metastasise to the lungs1. Such lesions can be 
managed with excision from the lung without progression of the disease.  
Distinguishing these 2 neoplasms is vital for delivery of appropriate clinical 
treatment, which involves neoadjuvant chemotherapy for patients with 
osteosarcoma. There is an exceptionally rare variant of osteosarcoma known as 
chondroblastoma-like osteosarcoma: this tumour resembles the histological 
phenotype of its benign counterpart but exhibits nuclear atypia and has a 
permeative growth pattern14. Unfortunately we have not had the opportunity to 
test such cases.  In our experience, chondroblastoma-like areas are seen 
occasionally alongside conventional areas of chondroblastic osteosarcoma, and 
therefore we consider that the term rarely needs to be used. 
Other rare tumours that on small biopsies may be considered as mimics of 
chondroblastoma include fibrous dysplasia with cartilaginous differentiation1, 4, 
and extra-axial chordomas15-17 but we have shown that these tumour types do not 
express K36M mutant protein. 
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Finally, the osteoclast-rich component of chondroblastoma overlaps with other 
osteoclast-rich lesions including giant cell tumour of bone, aneurysmal bone cyst 
non-ossifying fibroma, giant cell reparative granuloma of jaw, and osteoclast-rich 
and telangiectatic osteosarcoma. We have previously shown that these do not 
harbour a H3F3 p.K36M mutation3.  Although 96% of giant cell tumours of bone, 
and 70% of aneurysmal bone cysts harbour a H3F3A p.G34 substitution and a 
USP6 rearrangement respectively, there are no diagnostic biomarkers reported 
for the other osteoclast-rich mimics18-20. Hence, the K36M antibody is useful for 
excluding these diagnoses.  
 
In summary, our data show that this immuno-marker is highly specific for the 
p.K36M mutant protein. Hence, this H3F3 K36M antibody is a valuable diagnostic 
tool and can be used by pathologists to provide more accurate diagnoses quickly 
and at low cost.  
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